Our data suggest that the activation of FGF signaling confers resistance to CDK4/6 inhibitors and ET and that tasurgratinib shows antitumor activity in combination with ET in ET-resistant ER+ breast cancer. The gene discussed is CDK4; the disease is breast cancer.